CA2351488A1 - Substituted 4-amino-2-arylcyclopenta[d]pyrimidines, their preparation, their use and pharmaceutical preparations comprising them - Google Patents
Substituted 4-amino-2-arylcyclopenta[d]pyrimidines, their preparation, their use and pharmaceutical preparations comprising them Download PDFInfo
- Publication number
- CA2351488A1 CA2351488A1 CA002351488A CA2351488A CA2351488A1 CA 2351488 A1 CA2351488 A1 CA 2351488A1 CA 002351488 A CA002351488 A CA 002351488A CA 2351488 A CA2351488 A CA 2351488A CA 2351488 A1 CA2351488 A1 CA 2351488A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- substituted
- group
- formula
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to compounds of formula (I) wherein R1, R2 and R3 have the meanings given in the claims. Said compounds are valuable active agents in medicaments for the treatment and prophylaxis of diseases, for example cardiovascular diseases such as hypertension, angina pectoris, heart failure, thrombosis and atherosclerosis. The compounds of formula (I) are ab le to modulate the body's own production of cyclic guanosine monophosphate (cGM P) and are generally suitable for the treatment and prophylaxis ofisorders associated with an impaired cGMP balance. The invention also relates to methods for producing compounds of formula (I), to their use in the treatmen t and prophylaxis of the above diseases and in the preparation of medicaments for such diseases, and to pharmaceutical preparations containing the compoun ds of formula (I).
Claims (11)
1. A compound of the formula I, in which R1 and R2, which are independent of one another and can be identical or different, are hydrogen, or (C1-C8)-alkyl which can be substituted by one or more identical or different substituents from the group consisting of hydroxyl, (C1-C4)-alkoxy, (C1-C4)-alkyl-S(O)m-, phenyl, naphthyl and pyridyl, or (C3-C9)-cycloalkyl which can be substituted by one or more identical or different substituents from the group consisting of (C1-C4)-alkyl, hydroxyl, amino and benzyl, or the radical of a 5-membered to 7-membered saturated heterocyclic ring which contains one or two identical or different hetero ring members from the group consisting of O, NR10 and S(O)m and which can be substituted by one or more identical or different substituents from the group consisting of (C1-C4)-alkyl, hydroxyl and aryl-(C1-C4)-alkyl, where radicals phenyl, naphthyl, pyridyl and benzyl contained in the radicals or R2 can be unsubstituted or can be substituted in the aromatic ring by one or more identical or different substituents from the group consisting of halogen, (C1-C4)-alkyl, phenyl, CF3, NO2, OH, -O-(C1-C4)-alkyl, -O-(C2-C4)-alkyl-O-(C1-C4)-alkyl, (C1-C2)-alkylenedioxy, NH2, -NH-(C1-C4)-alkyl, -N((C1-C4)-alkyl)2, -NH-CHO, -NH-CO-(C1-C4)-alkyl, -CN, -CO-NH2, -CO-NH-(C1-C4)-alkyl, -CO-N((C1-C4)-alkyl)2, -CO-OH, -CO-O-(C1-C4)-alkyl, -CHO and -CO-(C1-C4)-alkyl, but where R1 and R2 cannot both simultaneously be hydrogen;
or the radical R1R2N is a radical, bonded via a ring nitrogen atom, of a 5-membered to 7-membered saturated heterocyclic ring which, in addition to the nitrogen atom carrying the radicals R1 and R2, can contain a further hetero ring member from the group consisting of O and S(O)m and which can be substituted by one or more identical or different substituents from the group consisting of (C1-C4)-alkyl, hydroxyl, (C1-C4)-alkoxy and R11R12N;
R3 is aryl but cannot be unsubstituted phenyl;
R10 is hydrogen, (C1-C4)-alkyl, aryl-(C1-C4)-alkyl-, hydroxy-(C1-C4)-alkyl-;
hydroxycarbonyl-(C1-C4)-alkyl-13 ((C1-C4)-alkoxycarbonyl)-(C1-C4)-alkyl-, R11R12N-CO-(C1-C4)-alkyl-, R13-SO2- or aryl;
R11 and R12 are identical or different radicals from the group consisting of hydrogen and (C1-C4)-alkyl;
R13 is (C1-C4)-alkyl, aryl or R11R12N;
aryl is phenyl, naphthyl or heteroaryl, which can all be substituted by one or more identical or different substituents from the group consisting of halogen, (C1-C4)-alkyl, phenyl, CF3, NO2, OH, -O-(C1-C4)-alkyl, -O-(C2-C4)-alkyl-O-(C1-C4)-alkyl, (C1-C2)-alkylenedioxy, NH2, -NH-(C1-C4)-alkyl, -N((C1-C4)-alkyl)2, -NH-CHO, -NH-CO-(C1-C4)-alkyl, -CN, -CO-NH2, -CO-NH-(C1-C4)-alkyl, -CO-N((C1-C4)-alkyl)2, -CO-OH, -CO-O-(C1-C4)-alkyl, -CHO and -CO-(C1-C4)-alkyl;
heteroaryl is the radical of a monocyclic 5-membered or 6-membered aromatic heterocycle or of a bicyclic 8-membered to 10-membered aromatic heterocycle, each of which contain one or more identical or different ring heteroatoms from the group consisting of N, O and S;
m is 0, 1 or 2;
in all its stereoisomeric forms and mixtures thereof in all ratios, and its physiologically tolerable salts.
or the radical R1R2N is a radical, bonded via a ring nitrogen atom, of a 5-membered to 7-membered saturated heterocyclic ring which, in addition to the nitrogen atom carrying the radicals R1 and R2, can contain a further hetero ring member from the group consisting of O and S(O)m and which can be substituted by one or more identical or different substituents from the group consisting of (C1-C4)-alkyl, hydroxyl, (C1-C4)-alkoxy and R11R12N;
R3 is aryl but cannot be unsubstituted phenyl;
R10 is hydrogen, (C1-C4)-alkyl, aryl-(C1-C4)-alkyl-, hydroxy-(C1-C4)-alkyl-;
hydroxycarbonyl-(C1-C4)-alkyl-13 ((C1-C4)-alkoxycarbonyl)-(C1-C4)-alkyl-, R11R12N-CO-(C1-C4)-alkyl-, R13-SO2- or aryl;
R11 and R12 are identical or different radicals from the group consisting of hydrogen and (C1-C4)-alkyl;
R13 is (C1-C4)-alkyl, aryl or R11R12N;
aryl is phenyl, naphthyl or heteroaryl, which can all be substituted by one or more identical or different substituents from the group consisting of halogen, (C1-C4)-alkyl, phenyl, CF3, NO2, OH, -O-(C1-C4)-alkyl, -O-(C2-C4)-alkyl-O-(C1-C4)-alkyl, (C1-C2)-alkylenedioxy, NH2, -NH-(C1-C4)-alkyl, -N((C1-C4)-alkyl)2, -NH-CHO, -NH-CO-(C1-C4)-alkyl, -CN, -CO-NH2, -CO-NH-(C1-C4)-alkyl, -CO-N((C1-C4)-alkyl)2, -CO-OH, -CO-O-(C1-C4)-alkyl, -CHO and -CO-(C1-C4)-alkyl;
heteroaryl is the radical of a monocyclic 5-membered or 6-membered aromatic heterocycle or of a bicyclic 8-membered to 10-membered aromatic heterocycle, each of which contain one or more identical or different ring heteroatoms from the group consisting of N, O and S;
m is 0, 1 or 2;
in all its stereoisomeric forms and mixtures thereof in all ratios, and its physiologically tolerable salts.
2. A compound of the formula I as claimed in claim 1, in which one of the radicals R1 and R2 is (C1-C8)-alkyl which can be substituted by one or more identical or different substituents from the group consisting of hydroxyl, (C1-C4)-alkoxy, (C1-C4)-alkyl-S(O)m-, unsubstituted or substituted phenyl and unsubstituted or substituted naphthyl, or is (C3-C9)-cycloalkyl which can be substituted by one or more identical or different substituents from the group consisting of (C1-C4)-alkyl, hydroxyl, amino and unsubstituted or substituted benzyl; and the other of the radicals R1 and R2 is hydrogen, or (C1-C8)-alkyl which can be substituted by one or more identical or different substituents from the group consisting of hydroxyl, (C1-C4)-alkoxy, (C1-C4)-alkyl-S(O)m-, unsubstituted or substituted phenyl and unsubstituted or substituted naphthyl, or is (C3-C9)-cycloalkyl which can be substituted by one or more identical or different substituents from the group consisting of (C1-C4)-alkyl, hydroxyl, amino and unsubstituted or substituted benzyl;
or R1R2N is a radical, bonded via a ring nitrogen atom, of a 5-membered, 6-membered or 7-membered saturated heterocyclic ring which, in addition to the nitrogen atom carrying the radicals R1 and R2, can additionally contain as a further hetero ring member an oxygen atom or a group S(O)m and which can be substituted by one or more identical or different substituents from the group consisting of (C1-C4)-alkyl, hydroxyl, (C1-C4)-alkoxy and R11R12N; in all its stereoisomeric forms and mixtures thereof in all ratios, and its physiologically tolerable salts.
or R1R2N is a radical, bonded via a ring nitrogen atom, of a 5-membered, 6-membered or 7-membered saturated heterocyclic ring which, in addition to the nitrogen atom carrying the radicals R1 and R2, can additionally contain as a further hetero ring member an oxygen atom or a group S(O)m and which can be substituted by one or more identical or different substituents from the group consisting of (C1-C4)-alkyl, hydroxyl, (C1-C4)-alkoxy and R11R12N; in all its stereoisomeric forms and mixtures thereof in all ratios, and its physiologically tolerable salts.
3. A compound of the formula I as claimed in claim 1 and/or 2, in which one of the radicals R1 and R2 is (C1-C4)-alkyl which can be substituted by one or more identical or different substituents from the group consisting of hydroxyl, (C1-C4)-alkoxy, (C1-C4)-alkyl-S(O)m-, unsubstituted or substituted phenyl and unsubstituted or substituted naphthyl, or (C3-C9)-cycloalkyl, which can be substituted by one or more identical or different substituents from the group consisting of (C1-C4)-alkyl, hydroxyl, amino and unsubstituted or substituted benzyl, and the other of the radicals R1 and R2 is hydrogen, or the radicals and R2 are identical or different (C1-C4)-alkyl which can be substituted by one or more identical or different substituents from the group consisting of hydroxyl, (C1-C4)-alkoxy, (C1-C4)-alkyl-S(O)m-, unsubstituted or substituted phenyl and unsubstituted or substituted naphthyl;
in all its stereoisomeric forms and mixtures thereof in all ratios, and its physiologically tolerable salts.
in all its stereoisomeric forms and mixtures thereof in all ratios, and its physiologically tolerable salts.
4. A compound of the formula I as claimed in one or more of claims 1 to 3, in which one of the radicals R1 and R2 is (C3-C9)-cycloalkyl which can be substituted by one or more identical or different substituents from the group consisting of (C1-C4)-alkyl, hydroxyl, amino and benzyl, and the other of the radicals R1 and R2 is hydrogen;
in all its stereoisomeric forms and mixtures thereof in all ratios, and its physiologically tolerable salts.
in all its stereoisomeric forms and mixtures thereof in all ratios, and its physiologically tolerable salts.
5. A compound of the formula I as claimed in claim 1 and/or 2, in which R1R2N
is a radical from the group consisting of piperidino, morpholino and thiomorpholino (and its S-oxide and S,S-dioxide); in all its stereoisomeric forms and mixtures thereof in all ratios, and its physiologically tolerable salts.
is a radical from the group consisting of piperidino, morpholino and thiomorpholino (and its S-oxide and S,S-dioxide); in all its stereoisomeric forms and mixtures thereof in all ratios, and its physiologically tolerable salts.
6. A compound of the formula I as claimed in one or more of claims 1 to 5, in which R3 is substituted phenyl; in all its stereoisomeric forms and mixtures thereof in all ratios, and its physiologically tolerable salts.
7. A process for the preparation of compounds of the formula I as claimed in one or more of claims 1 to 6, which comprises activating a 4-hydroxypyrimidine of the formula IV and then reacting it with an amine of the formula VI, where R1, R2 and R3 have the meanings indicated in claims 1 to 6.
8. A compound of the formula I as claimed in one or more of claims 1 to 6 and/or its physiologically tolerable salts for use as a pharmaceutical.
9. A pharmaceutical preparation, which contains one or more compounds of the formula I as claimed in one or more of claims 1 to 6 and/or its/their physiologically tolerable salts and a pharmaceutically tolerable carrier.
10. A compound of the formula I as claimed in one or more of claims 1 to 6 and/or its physiologically tolerable salts for use as activators of soluble guanylate cyclase.
11. A compound of the formula I as claimed in one or more of claims 1 to 6 and/or its physiologically tolerable salts for use in the therapy or prophylaxis of cardiovascular disorders, endothelial dysfunction, diastolic dysfunction, atherosclerosis, high blood pressure, angina pectoris, thromboses, restenoses, myocardial infarct, strokes, cardiac insufficiency, pulmonary hypertension, erectile dysfunction, bronchial asthma, chronic renal insufficiency, diabetes or liver cirrhosis or for improving restricted learning capacity or memory power.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19853278A DE19853278A1 (en) | 1998-11-19 | 1998-11-19 | New 4-amino-2-aryl-cyclopentapyrimidine derivatives are activators of soluble guanylate cyclase, useful for treating or preventing e.g. thrombosis and restenosis |
| DE19853278.4 | 1998-11-19 | ||
| PCT/EP1999/008382 WO2000031047A1 (en) | 1998-11-19 | 1999-11-03 | Substituted 4-amino-2-aryl-cyclopenta[d]pyrimidines, their production and use and pharmaceuticalreparations containing same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2351488A1 true CA2351488A1 (en) | 2000-06-02 |
| CA2351488C CA2351488C (en) | 2009-12-29 |
Family
ID=7888276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002351488A Expired - Fee Related CA2351488C (en) | 1998-11-19 | 1999-11-03 | Substituted 4-amino-2-arylcyclopenta[d]pyrimidines, their preparation, their use and pharmaceutical preparations comprising them |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US6627628B1 (en) |
| EP (1) | EP1131302B1 (en) |
| JP (1) | JP4695262B2 (en) |
| AT (1) | ATE316964T1 (en) |
| AU (1) | AU1159400A (en) |
| CA (1) | CA2351488C (en) |
| DE (2) | DE19853278A1 (en) |
| ES (1) | ES2257103T3 (en) |
| PT (1) | PT1131302E (en) |
| WO (1) | WO2000031047A1 (en) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19853278A1 (en) * | 1998-11-19 | 2000-05-25 | Aventis Pharma Gmbh | New 4-amino-2-aryl-cyclopentapyrimidine derivatives are activators of soluble guanylate cyclase, useful for treating or preventing e.g. thrombosis and restenosis |
| DE19904710A1 (en) | 1999-02-05 | 2000-08-10 | Aventis Pharma Gmbh | Substituted 4-amino-2-aryl-tetrahydroquinazolines, their preparation, their use and pharmaceutical compositions containing them |
| US7031977B2 (en) * | 2002-02-28 | 2006-04-18 | Plumtree Software, Inc. | Efficiently storing indented threads in a threaded discussion application |
| WO2004052862A1 (en) * | 2002-12-10 | 2004-06-24 | Ono Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic compounds and medicinal use thereof |
| JP4808156B2 (en) * | 2003-08-05 | 2011-11-02 | バーテックス ファーマシューティカルズ インコーポレイテッド | Condensed pyrimidine compounds as inhibitors of voltage-gated ion channels |
| BRPI0417354A (en) | 2003-12-03 | 2007-03-13 | Cytopia Res Pty Ltd | tubulin inhibitor compounds, compositions and their uses |
| TW200621257A (en) * | 2004-10-20 | 2006-07-01 | Astellas Pharma Inc | Pyrimidine derivative fused with nonaromatic ring |
| RU2481336C2 (en) * | 2006-07-06 | 2013-05-10 | Эррэй Биофарма Инк. | Cyclopenta(d)pyrimidines as protein kinase akt inhibitors |
| US8063050B2 (en) * | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| CN101516891B (en) | 2006-07-06 | 2013-06-05 | 阵列生物制药公司 | Dihydrothieno pyrimidines as AKT protein kinase inhibitors |
| CN101511842B (en) | 2006-07-06 | 2012-10-31 | 阵列生物制药公司 | Dihydrofuro pyrimidines as AKT protein kinase inhibitors |
| US9409886B2 (en) | 2007-07-05 | 2016-08-09 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| BRPI0813993A2 (en) * | 2007-07-05 | 2015-06-16 | Array Biopharma Inc | Pyrimidyl cyclopentanes as akt protein kinase inhibitors |
| US8846683B2 (en) | 2007-07-05 | 2014-09-30 | Array Biopharma, Inc. | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors |
| RU2486181C2 (en) | 2007-07-05 | 2013-06-27 | Эррэй Биофарма Инк. | Pyrimidyl cyclopentanes as akt/protein kinase inhibitors |
| EP2242755B1 (en) | 2008-01-08 | 2012-09-12 | Array Biopharma, Inc. | Pyrrolopyridines as kinase inhibitors |
| CN101965347B (en) | 2008-01-09 | 2013-01-02 | 阵列生物制药公司 | Pyrazolopyridines as kinase inhibitors |
| NZ586720A (en) | 2008-01-09 | 2012-11-30 | Array Biopharma Inc | Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor |
| NZ586346A (en) * | 2008-01-09 | 2012-02-24 | Array Biopharma Inc | Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors |
| KR20140022053A (en) | 2011-04-01 | 2014-02-21 | 제넨테크, 인크. | Combinations of akt and mek inhibitor compounds, and methods of use |
| CN103857395A (en) | 2011-04-01 | 2014-06-11 | 基因泰克公司 | Combinations of AKT inhibitor compounds and abiraterone, and methods of use |
| EP2938610A2 (en) * | 2012-12-28 | 2015-11-04 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof |
| CN113880859B (en) * | 2021-11-16 | 2022-06-21 | 江西科技师范大学 | 2-aryl-4-arylmethylamino pyrimidine compound and application thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3346452A (en) | 1963-08-19 | 1967-10-10 | Ciba Geigy Corp | 5, 6-lower alkylene-pyrimidines |
| DE4029654A1 (en) * | 1990-09-19 | 1992-04-02 | Hoechst Ag | 2-PHENYL-PYRIMIDINE, METHOD FOR THE PRODUCTION THEREOF, AGENTS CONTAINING IT AND THEIR USE AS FUNGICIDES |
| JP2928079B2 (en) | 1994-02-14 | 1999-07-28 | 永信薬品工業股▲ふん▼有限公司 | 1- (Substituted benzyl) -3- (substituted aryl) condensed pyrazoles, their production and use |
| JPH07228573A (en) * | 1994-02-16 | 1995-08-29 | Dainippon Pharmaceut Co Ltd | 2-phenylcycloalkanopyrimidine derivative |
| IL117659A (en) | 1995-04-13 | 2000-12-06 | Dainippon Pharmaceutical Co | Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same |
| WO1997047601A1 (en) | 1996-06-11 | 1997-12-18 | Yoshitomi Pharmaceutical Industries, Ltd. | Fused heterocyclic compounds and medicinal uses thereof |
| DE19642255A1 (en) | 1996-10-14 | 1998-04-16 | Bayer Ag | Use of 1-benzyl-3- (substituted-hetaryl) fused pyrazole derivatives |
| EE9900151A (en) | 1996-10-14 | 1999-12-15 | Bayer Aktiengesellschaft | Heterocyclylmethyl-substituted pyrazole derivatives |
| DE19836697A1 (en) | 1998-08-13 | 2000-02-17 | Hoechst Marion Roussel De Gmbh | New substituted 4-amino-2-aryl-pyrimidines, are soluble guanylate cyclase activators useful e.g. for treating atherosclerosis, hypertension, angina pectoris, thrombosis, asthma or diabetes |
| DE19853278A1 (en) * | 1998-11-19 | 2000-05-25 | Aventis Pharma Gmbh | New 4-amino-2-aryl-cyclopentapyrimidine derivatives are activators of soluble guanylate cyclase, useful for treating or preventing e.g. thrombosis and restenosis |
-
1998
- 1998-11-19 DE DE19853278A patent/DE19853278A1/en not_active Withdrawn
-
1999
- 1999-11-03 JP JP2000583875A patent/JP4695262B2/en not_active Expired - Fee Related
- 1999-11-03 AT AT99972626T patent/ATE316964T1/en active
- 1999-11-03 WO PCT/EP1999/008382 patent/WO2000031047A1/en active IP Right Grant
- 1999-11-03 CA CA002351488A patent/CA2351488C/en not_active Expired - Fee Related
- 1999-11-03 EP EP99972626A patent/EP1131302B1/en not_active Expired - Lifetime
- 1999-11-03 DE DE59913103T patent/DE59913103D1/en not_active Expired - Lifetime
- 1999-11-03 US US09/856,069 patent/US6627628B1/en not_active Expired - Lifetime
- 1999-11-03 PT PT99972626T patent/PT1131302E/en unknown
- 1999-11-03 ES ES99972626T patent/ES2257103T3/en not_active Expired - Lifetime
- 1999-11-03 AU AU11594/00A patent/AU1159400A/en not_active Abandoned
-
2003
- 2003-09-12 US US10/660,489 patent/US7138398B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1131302A1 (en) | 2001-09-12 |
| ATE316964T1 (en) | 2006-02-15 |
| AU1159400A (en) | 2000-06-13 |
| US6627628B1 (en) | 2003-09-30 |
| JP4695262B2 (en) | 2011-06-08 |
| WO2000031047A1 (en) | 2000-06-02 |
| US20040048850A1 (en) | 2004-03-11 |
| DE59913103D1 (en) | 2006-04-13 |
| PT1131302E (en) | 2006-05-31 |
| DE19853278A1 (en) | 2000-05-25 |
| CA2351488C (en) | 2009-12-29 |
| ES2257103T3 (en) | 2006-07-16 |
| US7138398B2 (en) | 2006-11-21 |
| EP1131302B1 (en) | 2006-02-01 |
| JP2002530385A (en) | 2002-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2351488A1 (en) | Substituted 4-amino-2-arylcyclopenta[d]pyrimidines, their preparation, their use and pharmaceutical preparations comprising them | |
| AU2270899A (en) | Substituted 2-aryl-4-amino-chinazolines, method for the production and use thereof as medicaments | |
| JP2006143737A5 (en) | ||
| JP2002530385A5 (en) | ||
| JP2002520309A5 (en) | ||
| ES8205749A1 (en) | 3-Amino-1,2-propane diols, process for their preparation, pharmaceutical compositions containing them and use thereof. | |
| US20020049190A1 (en) | Pharmaceutical compositions comprising metal complexes | |
| RU2006137716A (en) | HISTONDEACETYLASE INHIBITORS | |
| US10947225B2 (en) | Phosphotidylinositol 3-kinase inhibitors | |
| CN112920208B (en) | Boric acid-containing indole aryl sulfone derivative and preparation method and application thereof | |
| CA2336702A1 (en) | Sulfonylaminocarboxylic acid n-arylamides as guanylate cyclase activators | |
| JP2006514051A5 (en) | ||
| RU2002114041A (en) | N-GUANIDINOALKYLAMIDES, THEIR PRODUCTION, THEIR APPLICATION AND THEIR PHARMACEUTICAL DRUGS | |
| ATE255565T1 (en) | SUBSTITUTED 4-AMINO-2-ARYLTETRAHYDROQUINAZOLINES, THEIR PREPARATION, USE THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| NO952596L (en) | Ortho-amino-substituted benzoyl guandines, processes for their preparation, their use as a drug or diagnostic as well as drugs containing them | |
| GB1347935A (en) | Piperazine derivatives methods for their production and phar maceutical compositions containing them | |
| AU2725399A (en) | Substituted isoindolones and their use as cyclic gmp modulators in medicaments | |
| CN108135916B (en) | Chiral specific boron-containing compounds and their use in the treatment of cancer or amyloidosis | |
| AU2002257644A1 (en) | Piperazine derivatives and their use as 5-ht1b ligands | |
| EP1261587B1 (en) | Stilbene derivatives, their preparation and their use as antiviral agents | |
| JPWO2005051927A1 (en) | Method for culturing CD4-positive T cells by stimulation culture of HIV-1-infected peripheral blood mononuclear cells, and HIV-1 growth inhibitor | |
| JP2007176876A (en) | New cxcr4 antagonist and application thereof | |
| EP0090552A3 (en) | Pentacyclic compounds | |
| ATE93524T1 (en) | MITOMYCINAL ANALOGUES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL PREPARATIONS. | |
| MY103236A (en) | Novel 2-thienyloxyacetic acid derivatives, a process for their preparation and pharmaceutical preparations containing them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20161103 |